Comparative effects of continuous infusion of mCPP, Ro 60‐0175 and d‐fenfluramine on food intake, water intake, body weight and locomotor activity in rats
- 1 July 2000
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (6) , 1305-1314
- https://doi.org/10.1038/sj.bjp.0703443
Abstract
1. The aim of the study was to compare the effects of 14 day subcutaneous infusion of the 5-HT(2C) receptor agonists, m-chlorophenylpiperazine (mCPP, 12 mg kg(-1) day(-1)) and Ro 60-0175 (36 mg kg(-1) day(-1)) and the 5-HT releasing agent and re-uptake inhibitor, d-fenfluramine (6 mg kg(-1) day(-1)), on food and water intake, body weight gain and locomotion in lean male Lister hooded rats. 2. Chronic infusion of all three drugs significantly reduced food intake and attenuated body weight gain. In contrast, drug infusion did not lead to significant reductions in locomotor activity in animals assessed 2 and 13 days after pump implantation. 3. In a subsequent 14 day study that was designed to identify possible tolerance during days 7 - 14, animals were given a subcutaneous infusion of mCPP (12 mg kg(-1) day(-1)) or d-fenfluramine (6 mg kg(-1) day(-1)) for either 7 or 14 days. During the first 7 days both drugs significantly reduced body weight gain compared to saline-infused controls; however, from day 7 onwards animals withdrawn from drug treatment exhibited an increase in body weight such that by day 14 they were significantly heavier than their 14-day drug-treated counterparts. 4. Both mCPP and d-fenfluramine reduced daily food intake throughout the infusion periods. For 14-day treated animals this hypophagia was marked during the initial week of the study but only minor during the second week. In light of the sustained drug effect on body weight, the data suggest that weight loss by 5-HT(2C) receptor stimulation may be only partly dependent on changes in food consumption and that 5-HT(2C) receptor agonists may have effects on thermogenesis. 5. These data suggest tolerance does not develop to the effects of d-fenfluramine, mCPP and Ro 60-0175 on rat body weight gain.Keywords
This publication has 48 references indexed in Scilit:
- Identification of an Endogenous 5‐Hydroxytryptamine2A Receptor in NIH‐3T3 Cells: Agonist‐Induced Down‐Regulation Involves Decreases in Receptor RNA and NumberJournal of Neurochemistry, 1997
- Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphanBritish Journal of Clinical Pharmacology, 1996
- Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphanBritish Journal of Clinical Pharmacology, 1996
- The lateral hypothalamic area revisited: Ingestive behaviorNeuroscience & Biobehavioral Reviews, 1996
- Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?Obesity Research, 1995
- Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptorsNature, 1995
- Novel regulation of 5-HT1C receptors: down-regulation induced both by 5-HT1C/2 receptor agonists and antagonistsEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Effect of continuous infusions of dexfenfluramine on food intake, body weight and brain amines in ratsLife Sciences, 1986
- Neurobiology of an anorectic drug: FenfluramineProgress in Neurobiology, 1986
- Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPPLife Sciences, 1985